Condyloma

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
1
AP611074 5% gelPhase 21 trial
Active Trials
NCT02724254CompletedEst. Jul 2018
C
CEL-SCIVA - Vienna
1 program
1
Leukocyte Interleukin, Injection 200IUPhase 11 trial
Active Trials
NCT02115919Terminated4Est. Jan 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VaxartAP611074 5% gel
CEL-SCILeukocyte Interleukin, Injection 200IU

Clinical Trials (2)

Total enrollment: 4 patients across 2 trials

NCT02724254VaxartAP611074 5% gel

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Start: Jan 2016Est. completion: Jul 2018
Phase 2Completed
NCT02115919CEL-SCILeukocyte Interleukin, Injection 200IU

Safety Study of Multikine in the Treatment of Perianal Warts

Start: Apr 2014Est. completion: Jan 20164 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space